FAQ

What is PlexoBio and how does it work?

PlexoBio is a leading marketplace and advisory platform that connects pharmaceutical and biotech companies with advanced preclinical models. Our services help accelerate drug discovery by providing access to cutting-edge technologies such as in silico models, organ-on-a-chip systems, and 3D cell cultures.

What types of preclinical models does PlexoBio offer?

We offer diverse selection of cutting-edge preclinical models designed to elevate your research:

Tumor Models: Specialized solutions for oncology studies, featuring tumor spheroids and organoids for precise experimentation.

In Silico Models: Sophisticated computational platforms offering predictive insights into drug interactions and efficacy.

Organ-on-a-Chip Systems: Innovative microfluidic devices that simulate human organ systems, enabling reliable and efficient drug evaluation.

3D Cell Cultures: Next-generation in vitro models replicating human tissue architecture for enhanced accuracy in drug testing.

What industries can benefit from PlexoBio’s services?

PlexoBio primarily serves the biotech, pharmaceutical, and biopharma industries, especially those focused on drug discovery, preclinical research, and therapeutic development. We also work with research institutions and academic labs looking to advance their research with state-of-the-art preclinical models.

How does PlexoBio ensure the quality of preclinical models?

PlexoBio partners with leading providers of preclinical models to ensure the highest standards of quality and reliability. Our platform carefully vets each provider, ensuring that only the best and most scientifically validated models are available to our clients. Additionally, our advisory team is committed to guiding you toward the most reliable and effective models for your research.